Elegen is the only DNA manufacturer delivering the unique combination of complexity, length and NGS-verified accuracy within days
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Additional capacity broadens Grace’s fine chemical capabilities for API production
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Both organisations enter into a long- term collaboration to expand patient access in India
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
Subscribe To Our Newsletter & Stay Updated
